mRNA vaccine platforms to prevent bacterial infections

Carson Bergstrom; Nicholas O Fischer; Jessica Z Kubicek-Sutherland; Zachary R Stromberg

doi:10.1016/j.molmed.2024.02.013

mRNA vaccine platforms to prevent bacterial infections

Trends Mol Med. 2024 Mar 13:S1471-4914(24)00038-8. doi: 10.1016/j.molmed.2024.02.013. Online ahead of print.

Authors

Carson Bergstrom¹, Nicholas O Fischer², Jessica Z Kubicek-Sutherland³, Zachary R Stromberg⁴

Affiliations

¹ Chemical and Biological Signatures Group, Pacific Northwest National Laboratory, Richland, WA, USA; Elson S. Floyd College of Medicine, Washington State University, Spokane, WA, USA.
² Physical and Life Sciences Directorate, Lawrence Livermore National Laboratory, Livermore, CA, USA.
³ Physical Chemistry and Applied Spectroscopy, Los Alamos National Laboratory, Los Alamos, NM, USA.
⁴ Chemical and Biological Signatures Group, Pacific Northwest National Laboratory, Richland, WA, USA. Electronic address: zachary.stromberg@pnnl.gov.

PMID: 38485647
DOI: 10.1016/j.molmed.2024.02.013

Abstract

Bacterial infections are an urgent public health priority. The application of mRNA vaccine technology to prevent bacterial infections is a promising therapeutic strategy undergoing active development. This article discusses recent advances and limitations of mRNA vaccines to prevent bacterial diseases and provides perspectives on future research directions.

Keywords: bacterial pathogen; mRNA vaccine; self-amplifying RNA; therapeutic; vaccine.